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we achieved what we set out to do, have the consequences of 
treatment been worth the outcome and is this economically viable. 
The collection of relevant data and its intelligent use is critical. Data 
that allows measurement of the impact of side effects of treatments 
both short and long term along a patients entire continuum of care, 
their global quality of life, the economic impact across the board and 
whether outcomes have influenced practice,  and policy  are all 
important. Knowing how cancer and treatment affect individuals is 
critical in trying to determine whether any intervention is effective, 
tolerable and acceptable. The Cancer Outcomes Measurement 
Working Group (COMWG) has provided a more inclusive method of 
global assessment(3). This Group describes current best practices and 
recommendations for assessing the following three outcomes across 
the continuum of care: health-related quality of life; economic 
burden; and patient satisfaction; 
The Radiation Oncology community has developed a scoring system for 
recording Common Toxicity Criteria both for acute and long term 
symptoms and collection of quality of life data in radiation oncology 
clinical trials is becoming routine(4). A number of radiation oncology 
and medical oncology trials groups have consumers involved in the 
development of trials and on the trial management committees along 
with experts in quality of life.   
For Interventional Oncology, having access to alarge and relevant data 
repository that allows for such global evaluation iscritical. Expanding 
data collection beyond the RECIST criteria to encompass themore 
global measures discussed above needs to become routine if 
interventional oncology treatments are to become incorporated into 
mainstream care, funded andvalued. 
1. Breakaway: The global burden of cancer—challenges and 
opportunities.  Economist Intelligence Unit Ltd 2009 
2. www.RECIST.com 
3. outcomes.cancer.gov/areas/assessment/comwg.html 
4. ctep.cancer.gov/reporting/ctc.html 
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Purpose/Objective: MRI has a high sensitivity for tumor detection and 
a good correlation with histopathology findings. The precision of 
preoperative target volume delineation on newly developed 3D supine 
CE-MRI was compared to preoperative delineation on CE-CT in 
patients treated with breast-conserving therapy.  
Materials and Methods: We tested a newly developed 3D high 
resolution MRI protocol for target volume delineation in RT supine 
position in 14 cT1-2N0 patients. Gross tumor volumes (GTVs) were 
delineated by 4 experienced breast radiation oncologists, following 
written delineation instructions, on preoperative contrast-enhanced 
(CE) CT (1x1 mm2 in plane resolution, 3 mm slice thickness) and 3D 
CE-MRI (voxel size 1.2x1.2x1.2 mm3). To assess whether differences in 
GTV delineation were also clinically relevant, clinical target volumes 
(CTVs) were created by addition of a 1.5 cm margin around the tumor 
volume excluding the skin and chest wall. Interobserver variability 
(IOV) was assessed by calculating the conformity index (CI) and the 
center of mass distance (dCOM) for both the GTV and CTV in each 
patient. Tumor characteristics on CE-CT and CE-MRI were assessed 
and scored by an experienced breast radiologist.  
Results: In figure 1, target volume delineations of the 4 observers are 
shown on both preoperative CE-CT and CE-MRI in the same patient.  
The median CI of the GTV was higher on CE-MRI compared to CE-CT 
(Table 1). After expansion to the CTV, this difference in CI was no 
longer statistically significant. However, an incorrect GTV was 
delineated on CE-CT in 2/14 patients (14%) by multiple observers (1/4 
and 3/4 observers in each misdelineated patient). This resulted in 
high ranges of the CI on CE-CT. 
Tumor shapes were rated as more irregular and spiculated on CE-MRI. 
This did not result in a decreased CI on CE-MRI. A uniform volume 
expansion of GTV to CTV resulted in larger volumes on CE-MRI 
compared to CE-CT. 
No difference in median dCOM was observed between both image 
modalities. 
 
 
 
CI Conformity Index, GTV gross tumor volume, CTV clinical target 
volume, dCOM center of mass distance. Mean volume and dCOM were 
calculated per patient, median values were calculated over the 
included patient population. 
Conclusions: Preoperative target volume delineation showed a higher 
precision on 3D CE-MRI compared to CE-CT. A more irregular and 
spiculated tumor was visualized on CE-MRI without a decrease of 
interobserver agreement. Future studies will focus on using 
preoperative CE-MRI guided delineation in preoperative, as well as 
additional information in postoperative, whole or accelerated partial 
breast irradiation. 
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Purpose/Objective: START A and START B studies have demonstrated 
a similar toxicity obtained by hypofractionation and standard 
fractionation in whole breast adjuvant radiotherapy. The aim of this 
study is the evaluation of hypofractionation effect on toxicity in our 
breast cancer patients.  
Materials and Methods: From 02/2009 to 01/2012 500 patients were 
treated with hypofractionated whole breast radiotherapy, 40 Gy/15 
fractions, delivered in 3 weeks, in our institution. Five patients had 
bilateral treatment. The median patient age was 62 yrs(28-91yrs). 
Table 1 Parameters of interobserver variability (n=14) 
 CT MRI  
 Median Range Median Range p-
value 
Mean volume 
(cm3) 
GTV  
CTV  
2.9 
54.0 
0.5 – 14.9  
30.3 –
112.8  
2.6  
60.9 
0.7 – 17.0 
34.5 –
129.4 
0.47 
0.02 
Conformity index 
GTV  
CTV  
0.52 
0.81 
0.24 – 0.67 
0.38 – 0.85 
0.60  
0.82  
0.48 – 0.74 
0.77 – 0.87 
<0.01 
0.11 
Mean dCOM (mm)  
GTV  
CTV  
1.5 
1.7 
0.6 – 39.6 
1.1 – 39.4  
1.2 
1.7 
0.5 – 2.3  
0.8 – 3.4 
0.08 
0.60 
 
 
